Study of Asoprisnil in the Treatment of Uterine Fibroids.

NCT ID: NCT00156156

Last Updated: 2008-05-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 149 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-11-30
• Study Completion Date: 2007-02-28

Brief Summary

The objective of this study is to determine the long-term safety of asoprisnil in women with abnormal uterine bleeding associated with uterine fibroids.

Detailed Description

No medical therapy is currently available for the long-term treatment of abnormal uterine bleeding associated with uterine fibroids in women and many women must resort to surgery for relief. The objective of this study is to determine the long-term safety of two asoprisnil doses (10 and 25 mg tablets) administered daily to women who received asoprisnil in one of the asoprisnil long-term studies (study C03-062 or study M01-391). The safety endpoints for this study will include the affects of asoprisnil on the endometrium, ovaries, bone (a subset of study M01-391 subjects), lipid profiles, adverse events, and changes from baseline lab values and vital signs.

Some subjects receiving asoprisnil developed endometrial changes. As a result, dosing was prematurely discontinued for all subjects. To ensure safety, subjects will remain on study and will undergo scheduled study procedures. In most subjects, endometrial changes reversed after asoprisnil discontinuation.

Conditions

Fibroid Uterus; Leiomyoma; Menorrhagia; Metrorrhagia; Uterine Fibroids

Keywords

Symptomatic Uterine Fibroids; Excessive Uterine Bleeding; Uterine Hemorrhage

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

1

Group Type: EXPERIMENTAL

Asoprisnil

Intervention Type: DRUG

Asoprisnil 10 mg Tablet, oral Daily for up to 2 years

2

Group Type: EXPERIMENTAL

Asoprisnil

Intervention Type: DRUG

Asoprisnil 25 mg Tablet, oral Daily for up to 2 years

Interventions

Asoprisnil

Asoprisnil 10 mg Tablet, oral Daily for up to 2 years

Intervention Type: DRUG

Asoprisnil

Asoprisnil 25 mg Tablet, oral Daily for up to 2 years

Intervention Type: DRUG

Other Intervention Names

J867; J867

Eligibility Criteria

Inclusion Criteria

• Women who have completed 12 months of active treatment in study M01-391 and Month 12 visit procedures Or completed 18 months of active treatment in study C03-062 and Month 18 visit procedures (with no more than a 14-day interruption in dosing from study C02-062 and this study) OR could not continue in a previous asoprisnil study, but are now eligible for retreatment
• Otherwise in good health
• Premenopausal based on Estrogen and FSH levels
• Adequate endometrial biopsy with no significant histological disorder
• Agrees to use double-barrier method of contraception

Exclusion Criteria

• Any abnormal lab or procedure result(s) the study-doctor considers important
• History of a blood-clotting disorder
• History of osteoporosis requiring treatment
• Any invasive procedure(s) (D&C, etc) where a polyp was confirmed or a surgical or invasive procedure for uterine fibroids was performed during any previous asoprisnil study
• Hemoglobin < 8.0 g/dL
• Endometrial thickness ≥ 19 mm

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Abbott

INDUSTRY

Sponsor Role: lead

Responsible Party

Abbott

Principal Investigators

Medical Director

Role: STUDY_CHAIR

Abbott

Other Identifiers

A-FB04-078

Identifier Type: -

Identifier Source: org_study_id